CEPI Allocates $3.9M for Ebola Vaccine Research in DRC
The Coalition for Epidemic Preparedness Innovations (CEPI) announced a $3.9 million funding initiative for research into the Bundibugyo Ebola virus in the Democratic Republic of the Congo (DRC). This funding will support three projects focused on utilizing disease surveillance, laboratory, genomic, and population-movement data to track the virus's spread and inform vaccine trials.
The largest project, B-REACT, will receive $2.5 million over 12 months. A second project led by Imperial College London will receive $1.1 million for mathematical modeling of outbreak scenarios and vaccine trials.
The third project, led by Makerere University School of Public Health, will receive $300,000 to model vaccination strategies. The funding comes amid a worsening Ebola outbreak in the DRC, with over 3,500 deaths reported and weekly cases in North Kivu nearly doubling.
CEPI's investment aims to enhance outbreak data utility for decision-makers and strengthen analytical capabilities in affected countries.
Plus234Feed summary based on reporting from Nairametrics. Read the original report below.
Read full article
Continue on Nairametrics
Get the week in one email
Top stories, NPFL results, the naira — every Friday morning. Free, one email a week.
Related Stories
WHO Allocates 20,000 Ervebo Doses for Ebola Trial
DRC Receives 70,000 Ebola Vaccine Doses Amid Outbreak
DRC Reports Over 8,000 Ebola Cases in Major Outbreak
US Pledges $267 Million to Combat Ebola in DRC
UN Warns Ebola Outbreak in DRC Outpaces Response Efforts
WHO Launches Experimental Ebola Study Amid Congo Outbreak
Get Plus234Feed on messaging apps
Same headlines, delivered where you already scroll.
